ACI’s Capitol Hill event, held of December 9, 2014, discussed the importance of speeding market entry to permit biosimilar competition. That competition would give consumers increased access to lower priced medicine, which would lead to better patient outcomes. Watch the event of the event.
WASHINGTON, Dec. 9, 2014 /PRNewswire-USNewswire/ — The American Consumer Institute Center for Citizen Research (ACI) today hosted an event on Capitol Hill bringing together a panel of experts highlighting the dramatic benefits that unimpeded biosimilars competition would mean for both patients and taxpayers. The event was held as the Food and Drug Administration (FDA) is […]
Agricultural production faces a steep challenge as the world population is expected to grow from 7 billion to 10 billion by 2050. Many aspects of agriculture and consumer expectations will change in order for another 3 billion people to sit at the table. The agricultural retooling will take place while nations juggle environmental factors such […]
Most of American’s activity is focused on work, education, entertainment, and social interactions. Some exercise intentionally to maintain their health and some get healthful exercise through their employment, but it’s unlikely that much of our attention is focused on health care. One sixth of our economy is tied to health care, but we can remain […]
The scheduling delay for a routine appointment with one of America’s 210,000 primary care doctors seems to be measured in weeks, even when the doctor’s practice is already the patient’s medical home. New patient appointments often take six weeks. For a good ophthalmologist, 2 or three months seems to be a normal wait. Medical care […]
Dr. Joseph Fuhr, Jr., professor of Economics and a senior fellow at ACI, wrote a piece on how biosimilar competition could provide wider choice and cheaper access to lifesaving drugs for patients, but the FDA needs to write the rules necessary to permit competitive entry. His piece is available to read and print at Forbes.
This article, written by ACI president Steve Pociask, discusses the benefits of biosimilar dugs. These drugs are generic-like versions of lifesaving brand named biopharmaceutical drugs, called biologics. Europe has had biosimilar competition since 2006, but the U.S. has yet to approve a single biosimilar drug for U.S. patients. The article calls on the FDA to accelerate its rulemaking and write […]
Just last week, Swiss drugmaker Novartis AG applied to create the first generic version of a brand named biologic drug for use in the United States. Their drug, a white blood cell stimulant, would be of great benefit to millions of cancer patients spending every last dime on incredibly expensive biologics. Generic versions of name […]
July 10, 2014 Ms. Margaret A. Hamburg Commissioner U.S. Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 Dear Commissioner Hamburg: On behalf of The American Consumer Institute (ACI), a nonprofit educational and research organization, we are writing to raise an issue of critical concern regarding the naming of biosimilar drugs. We […]
Today’s American Health & Drug Benefits (AH&DB) Journal, a peer-reviewed forum, published an article written by three ACI experts — Erwin A. Blackstone, Professor of Economics at Temple University; Joseph P. Fuhr, Jr., Professor of Economics at Widener University; and Steve Pociask, President of the American Consumer Institute, Center for Citizen Research. The article can […]